Profile data is unavailable for this security.
About the company
Sana Biotechnology, Inc. is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. The Company focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).
- Revenue in USD (TTM)0.00
- Net income in USD-269.48m
- Incorporated2018
- Employees421.00
- LocationSana Biotechnology Inc188 East Blaine Street, Suite 400SEATTLE 98102United StatesUSA
- Phone+1 (206) 701-7914
- Fax+1 (302) 636-5454
- Websitehttps://sana.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Castle Biosciences Inc | 137.04m | -67.14m | 603.80m | 542.00 | -- | 1.51 | -- | 4.41 | -2.58 | -2.58 | 5.26 | 15.03 | 0.3012 | 10.67 | 6.72 | 252,839.50 | -14.76 | -8.63 | -15.82 | -9.27 | 76.64 | 80.97 | -48.99 | -29.80 | 7.98 | -- | 0.0006 | -- | 45.65 | 58.37 | -114.55 | -- | 62.64 | -- |
| AnaptysBio Inc | 10.29m | -128.72m | 607.78m | 96.00 | -- | 2.37 | -- | 59.08 | -4.58 | -4.58 | 0.3653 | 9.19 | 0.0164 | -- | 8.96 | 107,156.30 | -20.54 | -14.77 | -21.25 | -15.44 | -- | -- | -1,251.33 | -226.33 | -- | -- | 0.00 | -- | -83.72 | 0.5675 | -122.72 | -- | 4.30 | -- |
| Amarin Corporation plc (ADR) | 369.19m | -105.80m | 609.17m | 365.00 | -- | 1.02 | -- | 1.65 | -0.2656 | -0.2656 | 0.9199 | 1.47 | 0.3778 | 0.4688 | 2.51 | 1,011,488.00 | -10.83 | -6.67 | -15.98 | -9.95 | 70.58 | 76.99 | -28.66 | -11.47 | 1.77 | -- | 0.00 | -- | -36.69 | 15.31 | -1,468.91 | -- | 118.60 | -- |
| ARS Pharmaceuticals Inc | 1.32m | -34.68m | 614.56m | 17.00 | -- | 2.24 | -- | 466.99 | -1.25 | -1.25 | 0.033 | 2.90 | 0.0043 | -- | -- | 77,411.77 | -11.28 | -- | -11.67 | -- | -- | -- | -2,635.41 | -- | -- | -- | 0.00 | -- | -- | -- | 61.24 | -- | -- | -- |
| Phibro Animal Health Corp | 972.05m | 36.24m | 620.52m | 1.86k | 17.12 | 2.31 | 8.86 | 0.6384 | 0.8948 | 0.8948 | 24.00 | 6.63 | 1.07 | 2.60 | 6.61 | 522,608.10 | 4.00 | 6.81 | 4.91 | 8.55 | 30.46 | 31.85 | 3.73 | 6.13 | 1.75 | 5.29 | 0.6396 | 35.89 | 13.07 | 4.28 | -9.58 | -5.31 | 12.15 | 3.71 |
| Sana Biotechnology Inc | 0.00 | -269.48m | 625.75m | 421.00 | -- | 1.25 | -- | -- | -1.43 | -1.43 | 0.00 | 2.61 | 0.00 | -- | -- | 0.00 | -27.61 | -- | -30.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.29 | -- | -- | -- |
| Rapt Therapeutics Inc | 1.53m | -83.84m | 629.17m | 97.00 | -- | 2.56 | -- | 412.03 | -2.58 | -2.58 | 0.0469 | 7.16 | 0.0066 | -- | -- | 15,742.27 | -36.07 | -45.24 | -38.02 | -48.64 | -- | -- | -5,490.37 | -2,745.89 | -- | -- | 0.00 | -- | -59.95 | -- | -21.15 | -- | -5.55 | -- |
| Harrow Health Inc | 88.60m | -14.09m | 634.12m | 217.00 | -- | 22.93 | -- | 7.16 | -0.5167 | -0.5167 | 3.23 | 0.9229 | 0.6929 | 4.72 | 16.53 | 408,271.90 | -11.02 | -5.92 | -12.35 | -7.02 | 71.35 | 69.81 | -15.90 | -6.95 | 6.00 | 0.0901 | 0.7927 | -- | 22.24 | 27.04 | 23.77 | -- | 27.46 | -- |
| Arcturus Therapeutics Holdings Inc | 206.00m | 9.35m | 636.53m | 170.00 | 70.94 | 2.35 | 58.53 | 3.09 | -0.0563 | -0.0563 | 7.60 | 10.18 | 0.4886 | -- | 67.20 | 1,211,759.00 | 2.22 | -25.20 | 3.03 | -31.59 | -- | -- | 4.54 | -118.84 | -- | 7.94 | 0.1833 | -- | 1,566.79 | 73.78 | 104.59 | -- | 98.45 | -- |
| Bicycle Therapeutics PLC (ADR) | 14.46m | -112.72m | 638.55m | 236.00 | -- | 2.35 | -- | 44.15 | -3.80 | -3.80 | 0.4876 | 9.06 | 0.0325 | -- | 9.50 | 61,283.90 | -25.32 | -26.32 | -28.15 | -29.28 | -- | -- | -779.35 | -492.29 | -- | -- | 0.1007 | -- | 23.65 | 47.67 | -68.69 | -- | 76.36 | -- |
| Mineralys Therapeutics Inc | 0.00 | -29.80m | 639.82m | 12.00 | -- | -- | -- | -- | -0.8042 | -0.8042 | 0.00 | 2.87 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -53.54 | -- | -- | -- |
| Sinovac Biotech Ltd. | 9.61bn | 3.84bn | 639.90m | 4.28k | -- | -- | 0.0941 | 0.0666 | 33.66 | 33.66 | 84.20 | 95.15 | 0.6937 | 2.06 | 8.13 | 2,243,901.00 | 48.08 | 128.51 | 83.54 | 225.07 | 92.77 | 94.07 | 69.30 | 71.98 | 22.75 | -- | 0.0013 | -- | 3,694.36 | 205.82 | 8,008.46 | -- | 124.40 | -- |
| Hillevax Inc | 0.00 | -159.81m | 648.84m | 62.00 | -- | 2.33 | -- | -- | -5.08 | -5.08 | 0.00 | 7.10 | 0.00 | -- | -- | 0.00 | -71.93 | -- | -157.01 | -- | -- | -- | -- | -- | -- | -- | 0.0525 | -- | -- | -- | -56.05 | -- | -- | -- |
| Dyne Therapeutics Inc | 0.00 | -168.10m | 649.02m | 123.00 | -- | 2.54 | -- | -- | -3.24 | -3.24 | 0.00 | 4.54 | 0.00 | -- | -- | 0.00 | -45.93 | -- | -49.79 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.60 | -- | -- | -- |
| Exscientia PLC (ADR) | 30.28m | -123.00m | 651.71m | 287.00 | -- | 1.03 | -- | 21.52 | -1.01 | -1.01 | 0.249 | 5.13 | 0.05 | 154.93 | 6.25 | 105,496.90 | -20.32 | -- | -23.43 | -- | -16.44 | -- | -406.22 | -- | 7.55 | -- | 0.013 | -- | 182.87 | -- | -120.94 | -- | -- | -- |
Data as of Mar 31 2023. Currency figures normalised to Sana Biotechnology Inc's reporting currency: US Dollar USD
31.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 31 Dec 2022 | 10.76m | 5.64% |
| Canada Pension Plan Investment Boardas of 31 Dec 2022 | 10.18m | 5.34% |
| The Vanguard Group, Inc.as of 31 Dec 2022 | 8.83m | 4.63% |
| SSgA Funds Management, Inc.as of 31 Dec 2022 | 6.79m | 3.56% |
| BlackRock Fund Advisorsas of 31 Dec 2022 | 6.61m | 3.47% |
| The Public Sector Pension Investment Boardas of 31 Dec 2022 | 6.40m | 3.36% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2022 | 4.26m | 2.24% |
| Crestline Management LPas of 31 Dec 2022 | 3.37m | 1.77% |
| Geode Capital Management LLCas of 31 Dec 2022 | 1.81m | 0.95% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2022 | 1.80m | 0.95% |
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
